India lets Actos back onto market, with warnings; Regeneron's Eylea sales slow; GSK files for new Cervarix approval;

@FiercePharma: Looking for a sales job? Lundbeck to hire > 200 to market antidepressant Brintellix, in prep for FDA nod. More | Follow @FiercePharma

@CarlyHFierce: In Vivus earnings, not a lot of revenue, but analysts seem optimistic about Zook's plans for Qsymia. Release | Follow @CarlyHFierce

> India has reversed itself on the diabetes drug Actos, allowing the treatment and its generics back onto the market, provided manufacturers add bladder-cancer warnings to its labeling. Report

> Sales of Regeneron's ($REGN) fast-growing eye drug Eylea slowed in the second quarter as existing patients moved to less-frequent dosing. Report

> India's Ranbaxy Laboratories posted an unexpected loss of 5.24 billion rupees, or about $85.28 million, on foreign exchange losses and goodwill charges; sales dropped by 17.8% as well. Report

> GlaxoSmithKline ($GSK) asked European regulators to approve a new, two-dose schedule for its human papillomavirus vaccine Cervarix; the currently approved schedule requires three doses. Report

> In a draft assessment, German pricing authorities determined that Almirall's irritable bowel syndrome treatment Constella offered no added benefit compared with existing treatments. Report

> German drugmaker Stada said its executive committee member in charge of production, Axel Mueller, had resigned for personal reasons on "most agreeable terms." Report

> Indian pricing regulators were to meet today with drugmakers about the implementation of new price controls. Report

Medical Device News

@FierceMedDev: Navidea's losses widen as it waits for Lymphoseek to catch on. Article | Follow @FierceMedDev

@DamianFierce: Israel's Given Imaging had a record Q2 and believes better things are on the horizon. Report | Follow @DamianFierce

> Gene By Gene grabs GE-backed diagnostics startup. More

> Roche Dx cuts more diabetes jobs amid faltering sales. Report

> Medtronic implant could point to future of Parkinson's treatment. Story

Biotech News

@FierceBiotech: Report: Seattle biotech VLST unloads assets and shuts doors. More | Follow @FierceBiotech

@JohnCFierce: Acceleron pitches $75M IPO as Celgene pushes partnership through PhII. News | Follow @JohnCFierce

@RyanMFierce: Now that "microbiome" means something to people... NuMe Health changes name to MicroBiome Therapeutics. Release | Follow @RyanMFierce

@EmilyMFierce: The Smithsonian plans to create a huge bank of genetic samples to enable large-scale genome sequencing. More | Follow @EmilyMFierce

> Vaxart garners $20M VC round for vaccine pills. Item

> Report: Determined Amgen sweetens its bid for Onyx Pharma. Story

> FDA experts give Bayer's riociguat unanimous backing for lung disease. Article

Biomarkers News

> Biomarker IDs cancer patients most likely to respond to EGFR inhibitors. Item

> NIH pushes for biomarker research to catch up with needs of kids. Story

> Are cancer biomarker tests grossly underused? More

> Elevated carbon monoxide levels in breath can point to infection. Story

> Broad, Dana-Farber license lung cancer biomarker IP to MolecularMD. Article

> Altered enzyme indicates Alzheimer's-like dementia. Item

Drug Delivery News

@MichaelGFierce: 'Soft robotic' hydrogel arms show drug delivering capability. More | Follow @MichaelGFierce

> UCSD surgeons deliver cancer drugs to brain with ClearPoint MRI tech. Story

> 3M sells dry powder inhaler rights to Adamis. News

> Next-gen Alzheimer's drug targets brain enzyme. Story

> Ocular Therapeutix nets FDA panel meeting for eye surgery hydrogel. Item

> Halozyme regrouping after ViroPharma trial flop. Article

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.